Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biological Chemistry
AstraZeneca, Columbia To Study Neurogenesis
by Lisa M. Jarvis
October 20, 2008
| A version of this story appeared in
Volume 86, Issue 42
AstraZeneca and Columbia University Medical Center have inked a research pact centered on neurology. The partners will study how neurogenesis, or the creation of neuronal cells, in adult brains could lead to new routes for treating depression and anxiety. Scientists only recently discovered that neurogenesis can occur in the adult brain; the hope is to tap into the power of those new neurons to stimulate the hippocampus and, ultimately, treat neurological disorders. In June, AstraZeneca and Columbia established a research collaboration focused on metabolic diseases.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter